In order to continue supporting customers and partners as best as possible, at ZEISS we are doing everything we can to protect our employees’ health and safety as well as maintain production in our plants and ensure our service operations.
In January, ZEISS set up a dedicated task force. We are closely assessing the latest developments together with government agencies and healthcare authorities on an ongoing basis. Decisions are made daily regarding the most sensible measures for ZEISS to take.
Of course, we will continue to be available for our customers as best we can. Some employees in individual areas are currently working remotely but can still be reached at their usual phone numbers and email addresses.
However, should our customers experience any disruptions in service at some of our sites and sales offices, we can also be contacted on these numbers.
All over the world, the company and its employees are joining the fight against the spread and consequences of the coronavirus pandemic. Read more
8 February 2021
Carl Zeiss Meditec generated revenue of €368.9m in the first three months of fiscal year 2020/21 (prior year: €369.7m), corresponding to a decline of just -0.2% (adjusted for currency effects: +2.6%) compared with the year-ago period, which had not yet been impacted by the COVID-19 pandemic. Earnings before interest and tax (EBIT) increased to €73.4m (prior year: €56.8m). The EBIT margin was 19.9% (prior year: 15.4%).
28 January 2021
The ZEISS Innovation Hub @ KIT on the North Campus of the Karlsruhe Institute of Technology (KIT) commenced operations back in January 2020, but has not been able to hold an official opening due to the pandemic – until yesterday, that is, when the opening was honored in a virtual ceremony.
19 January 2021
Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 368.9 million in the first quarter of fiscal year 2020/21 (previous year: EUR 369.7 million). This corresponds to a revenue development of -0.2% vs. the past year (after adjustment for currency effects: +2.6%).